Elicio Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
348
across all filing types
Latest filing
2026-03-17
Regulatory Filings
Country
US
United States of America
Listing
US
ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer) | 2026-03-17 | English | |
| S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-03-02 | English | |
| S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-02-27 | English | |
| 4 Filing | 2026-02-03 | English | |
| 4 Filing | 2026-02-03 | English | |
| 4 Filing | 2026-02-03 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 32962991 | EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer) | 2026-03-17 | English | ||
| 32894877 | S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-03-02 | English | ||
| 32894878 | S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-02-27 | English | ||
| 30835747 | 4 Filing | 2026-02-03 | English | ||
| 30835717 | 4 Filing | 2026-02-03 | English | ||
| 30835672 | 4 Filing | 2026-02-03 | English | ||
| 30835652 | 4 Filing | 2026-02-03 | English | ||
|
2025
8 filings
| |||||
| 12755907 | FORM 4 | 2025-12-10 | English | ||
| 12755908 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 12755909 | S-3 | 2025-11-13 | English | ||
| 12755910 | 10-Q | 2025-11-13 | English | ||
| 12755912 | 8-K | 2025-11-13 | English | ||
| 12755914 | Major Shareholding Notification 2025 | 2025-10-07 | English | ||
| 12755911 | 8-K | 2025-09-17 | English | ||
| 12755913 | 8-K | 2025-08-12 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on…
|
ASAP | SE | Professional, scientific and te… |
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Avalyn Pharma Inc.
Developing innovative inhaled therapies for rare respirator…
|
AVLN | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
Elicio Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33784/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33784 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33784 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33784 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33784}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Elicio Therapeutics, Inc. (id: 33784)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.